Cancer
-
Cancer experts going from strength to strength
Posted on:
A special visit by two international cancer specialists could mark the start of a valuable collaborative partnership. Professor Matthew Katz from the MD Anderson Cancer Centre in Houston Texas is recognised as a pioneer in the treatment of pancreatic cancer, while Professor Cynthia Sears from the Johns Hopkins University School of Medicine in Baltimore is
Category:
-
Partnership to drive innovation in genomic science
Posted on:
An exciting partnership between AGRF Ltd (Australian Genome Research Facility) and the University of Sydney and the Kolling Institute will help strengthen genomic capabilities. The partnership will see a specialised team and cutting-edge technology located within the institute to progress research in this increasingly crucial field. As Australia’s largest provider of genomic services, AGRF supports
-
Kolling Research Symposium 2024
Posted on:
We would like to thank everyone involved in the 2024 Kolling Institute Symposium. During the event, a diverse collection of researchers detailed the latest progress with their ground-breaking work into kidney and heart disease treatments, bone and muscle conditions, rare cancers, and neurological challenges. There was a focus too on the innovative work to develop
-
Kolling NEWS
Posted on:
Our Kolling Institute newsletter brings together a collection of profiles on our impressive researchers. Flip through our flipping book to discover more about our leading research into kidney disease, rare cancers and the use of supplements for osteoarthritis. There’s a focus too on the first steps towards gene therapy for Meniere’s disease, the latest research into treatments for
-
Spotlight on clinical trials
Posted on:
Kolling Institute researcher and Royal North Shore Hospital endocrinologist Professor Rory Clifton-Bligh has been involved in clinical trials for more than 20 years, focusing on conditions such as osteoporosis, thyroid cancer and diabetes. Patients in the endocrinology clinic have sometimes accessed medication 10 years ahead of other Australians. Many of these drugs have gone on
Category:
-
Innovation at the Kolling’s core
Posted on:
In the heart of the Kolling Institute, a world-renowned research centre, a raft of clinical trials is driving the future of healthcare. “Clinical trials are intrinsic to research,” says Professor James Elliott, Academic Director of the institute. “They help us test something so that we can better inform care for patients with various conditions who
-
Philanthropic funds launch crucial research into little-known cancer
Posted on:
Generous community support is strengthening our research into oesophageal cancer, lifting hopes of improved treatments for the aggressive and deadly cancer. The Fight for a Cure charity has donated $100,000 towards Dr Colby Stevenson’s research, on top of a $100,000 donation from the Howlett family, in memory of their son Scott who died from the
Category:
-
Leading new centre to strengthen cancer research and expertise
Posted on:
Researchers at the Kolling Institute have welcomed the launch of Australia’s premier cancer clinical trials centre on the Royal North Shore Hospital campus. NORTH Sydney Trials and Research Van Norton Poche or NORTH STAR VNP has been made possible by a $20 million gift from the late Kay Van Norton Poche and her husband Greg.
Category:
-
Valuable new funds support game-changing cancer research
Posted on:
Our ground-breaking leukaemia research at the Kolling Institute has received an important boost with the Cancer Council NSW announcing a $450,000 grant for Associate Professor Jenny Wang and her research team. The funds will help the development of a new therapy to greatly improve survival rates for those with acute myeloid leukaemia. This form of
Category:
-
Kolling researchers make promising breakthrough with leukaemia study
Posted on:
While there has been a great deal of encouraging progress with many cancer treatments over the last decade, the prognosis for people with acute myeloid leukaemia remains dismal, with only 27 per cent of patients surviving more than five years after treatment. Lead researcher Dr Jenny Wang said we have seen a sharp rise in
Category:
Copyright © 2026 Kolling Institute
All rights reserved